Uri Weinberg, M.D., Ph.D.
Chief Medical & Innovation Officer
Uri Weinberg, MD, PhD has served as Novocure’s Chief Innovation Officer since January 2023, and in March 2026 was appointed as Chief Medical Officer. In these dual roles, Dr. Weinberg oversees medical affairs, medical safety, and clinical development operations, as well as pre-clinical and early-stage innovations for TTFields therapy.
Dr. Weinberg previously served as Novocure’s Chief Science Officer from 2019 to 2023.
Dr. Weinberg joined Novocure in 2008 and managed the company’s first clinical trial in lung cancer, as well as the Phase 3 EF-14 clinical trial in newly diagnosed glioblastoma, which supported the approval of Optune Gio. Dr. Weinberg was also responsible for building Novocure’s global clinical development, clinical operations and real-world evidence functions.
Dr. Weinberg holds an M.D. Ph.D. from the Technion – Israel Institute of Technology.